Avalo Therapeutics, Inc. (AVTX) Q2 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Avalo Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.009 -- 00:00:03.591 star and zero on your telephone keypad. 00:00:03.591 -- 00:00:07.033 As a reminder, this conference is being recorded. 00:00:07.033 -- 00:00:12.636 It is now my pleasure to introduce your host, Megan Bacon, Director IR and Marketing. 00:00:12.636 -- 00:00:15.076 Please go ahead. 00:00:16.378 -- 00:00:21.661 Thank you and welcome to Horizon Technology Finance Corporation's second quarter 2024 00:00:21.661 -- 00:00:26.984 conference call. Representing the company today are Rob Pomeroy, Chairman and Chief Executive 00:00:26.984 -- 00:00:32.423 Officer, Jerry Michaud, President, Dan Dvoracic, Chief Operating Officer 00:00:32.423 -- 00:00:37.266 and Chief Investment Officer, and Dan Trollio, Chief Financial Officer. 00:00:37.266 -- 00:00:42.310 I would like to point out that the Q2 earnings press release and Form 10-Q are available 00:00:42.310 -- 00:00:46.111 on the company's website at horizontechfinance.com. 00:00:46.553 -- 00:00:51.096 Before we begin our formal remarks, I need to remind everyone that during this conference 00:00:51.096 -- 00:00:55.499 call, the company will make certain forward-looking statements, including statements 00:00:55.499 -- 00:00:58.655 with regard to the future performance of the company. 00:00:58.655 -- 00:01:03.858 Words such as believes, expects, anticipates, intends, or similar 00:01:03.858 -- 00:01:07.920 expressions are used to identify forward-looking statements. 00:01:07.920 -- 00:01:12.183 These forward-looking statements are subject to the inherent uncertainties in predicting 00:01:12.183 -- 00:01:14.544 future results and conditions. 00:01:14.544 -- 00:01:19.907 Certain factors could cause actual results to differ on a material basis from those projected 00:01:19.907 -- 00:01:24.516 in these f...